Pharma Foods International
Pharma Foods International Co., Ltd.
Company highlights
The largest segment by revenue is BtoC事業, at 87.0% of the total.
Key figures
Period Aug 2024 to Jul 2025ConsolidatedJapanese GAAP
Company profile
Tables scroll sideways
Disclosed data
Business activities and revenue composition
Pharma Foods International
Revenue and profit by business segment
Period Aug 2024 to Jul 2025Source Annual securities reportsConsolidated・Disclosed
| Business | Net sales to external customers | Operating income | ||||
|---|---|---|---|---|---|---|
| This year | Share | Last year | This year | Margin | Last year | |
| BtoC事業 | ¥56.7 billion | 87.0% | ¥52.5 billion | ¥3.7 billion | 6.5% | ¥5.3 billion |
| BtoB事業 | ¥8.2 billion | 12.5% | ¥9.1 billion | ¥1.2 billion | 15.3% | ¥1.6 billion |
| バイオメディカル事業 | ¥0.3 billion | 0.5% | ¥0.5 billion | ¥-0.4 billion | -114.2% | ¥-0.3 billion |
| Total of the businesses | ¥65.2 billion | 100.0% | ||||
Revenue and profit
Pharma Foods International
Period Aug 2024 to Jul 2025Source Annual securities reports
Amounts by account
| Group | Account | Amount | Consolidated / Non-consolidated |
|---|---|---|---|
| Selling, general and administrative expenses | Advertising expenses | ¥36.7 billion | Consolidated |
| Other | ¥7.6 billion | Consolidated | |
| Commission fees | ¥4.4 billion | Consolidated | |
| Freightage expenses | ¥2.0 billion | Parent only | |
| Research and development expenses | ¥1.4 billion | Consolidated | |
| Amortization of goodwill | ¥53.00 million | Consolidated | |
| Depreciation | ¥40.00 million | Parent only | |
| Provision of allowance for doubtful accounts | ¥-2.00 million | Parent only | |
| Profit by stage | Gross profit (loss) | ¥52.6 billion | Consolidated |
| Ordinary income | ¥2.6 billion | Consolidated | |
| Operating income | ¥2.4 billion | Consolidated | |
| Net income | ¥0.4 billion | Consolidated |
Pharma Foods International
Selling, general and administrative expenses
Period Aug 2024 to Jul 2025Source Annual securities reports
- Advertising expenses ¥36.7 billion
- Other ¥7.6 billion
- Commission fees ¥4.4 billion
- Freightage expenses ¥2.0 billion
- Research and development expenses ¥1.4 billion
- Amortization of goodwill ¥0.1 billion
Performance, financial position and capital allocation
Long-term changes in performance
Pharma Foods International
Long-term revenue, profit and asset trends
Period 2012 to 2025Source Annual securities reportsDisclosed
Pharma Foods International
Recent performance trends
Source Annual securities reports
Year-on-year comparison
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net sales | ¥46.8B | ¥60.2B | ¥68.6B | ¥62.1B | ¥65.3B |
| Year on year (%) | +204.5%◆ | +28.7%◆ | +13.9% | -9.4% | +5.0% |
| Ordinary income (loss) | ¥5.8B | ¥1.3B | ¥3.5B | ¥5.2B | ¥2.6B |
| Change from prior year | +631.0% | -78.1% | +180.1% | +48.3% | -51.4% |
| Ordinary income (loss) as a share of Net sales | 12.3% | 2.1% | 5.2% | 8.4% | 3.9% |
| Change (percentage points) | +7.2 points◆ | -10.2 points◆ | +3.1 points◆ | +3.3 points◆ | -4.5 points◆ |
Fiscal periods marked for changes
Earlier fiscal periods (9)
- 2013Net sales year on year +24.4%, Ordinary income (loss) as a share of revenue +10.3 points
- 2014Ordinary income (loss) as a share of revenue -19.6 points
- 2015Net sales year on year +34.1%, Ordinary income (loss) as a share of revenue -14.1 points, Ordinary income (loss) profit to loss
- 2017Net sales year on year +36.5%, Ordinary income (loss) as a share of revenue +2.3 points
- 2018Net sales year on year +68.2%
- 2019Net sales year on year +32.6%
- 2020Net sales year on year +45.8%
- 2021Net sales year on year +204.5%, Ordinary income (loss) as a share of revenue +7.2 points
- 2022Net sales year on year +28.7%, Ordinary income (loss) as a share of revenue -10.2 points
- 2023Ordinary income (loss) as a share of revenue +3.1 points
- 2024Ordinary income (loss) as a share of revenue +3.3 points
- 2025Ordinary income (loss) as a share of revenue -4.5 points
Pharma Foods International
Earnings and net assets per share over time
Unit yenSource Annual securities reports
Pharma Foods International
Return on equity over time
Unit %Source Annual securities reports
Consolidated indicators (15 items)
| Item | 4 years ago | 3 years ago | 2 years ago | Last year | This year |
|---|---|---|---|---|---|
| Net sales | ¥46.8 billion | ¥60.2 billion | ¥68.6 billion | ¥62.1 billion | ¥65.3 billion |
| Ordinary income (loss) | ¥5.8 billion | ¥1.3 billion | ¥3.5 billion | ¥5.2 billion | ¥2.6 billion |
| Net income (loss) attributable to owners of parent | ¥3.8 billion | ¥-0.4 billion | ¥3.1 billion | ¥3.2 billion | ¥0.4 billion |
| Comprehensive income | ¥3.8 billion | ¥-0.3 billion | ¥3.4 billion | ¥3.4 billion | ¥-3.00 million |
| Net assets | ¥8.5 billion | ¥7.1 billion | ¥9.6 billion | ¥11.6 billion | ¥11.5 billion |
| Total assets | ¥20.9 billion | ¥31.2 billion | ¥36.2 billion | ¥36.6 billion | ¥32.6 billion |
| Net assets per share | 291.25 yen | 243.65 yen | 333.88 yen | 412.71 yen | 399.95 yen |
| Basic earnings (loss) per share | 132.21 yen | -12.89 yen | 106.7 yen | 112.71 yen | 12.83 yen |
| Diluted earnings per share | 132.14 yen | Could not be retrieved | Could not be retrieved | Could not be retrieved | Could not be retrieved |
| Equity-to-asset ratio | 40.4% | 22.7% | 26.6% | 31.7% | 35.4% |
| Return on equity | 57.5% | -4.8% | 36.9% | 30.2% | 3.2% |
| Net cash provided by (used in) operating activities | ¥5.9 billion | ¥-6.1 billion | ¥6.1 billion | ¥5.5 billion | ¥-1.1 billion |
| Net cash provided by (used in) investing activities | ¥-0.4 billion | ¥-2.5 billion | ¥-1.0 billion | ¥-1.4 billion | ¥-0.9 billion |
| Net cash provided by (used in) financing activities | ¥1.0 billion | ¥7.7 billion | ¥2.3 billion | ¥-4.8 billion | ¥-4.5 billion |
| Cash and cash equivalents | ¥9.8 billion | ¥8.8 billion | ¥16.3 billion | ¥15.6 billion | ¥9.1 billion |
Parent only indicators (15 items)
| Item | 4 years ago | 3 years ago | 2 years ago | Last year | This year |
|---|---|---|---|---|---|
| Net sales | ¥38.0 billion | ¥43.1 billion | ¥44.8 billion | ¥40.6 billion | ¥42.2 billion |
| Ordinary income (loss) | ¥6.4 billion | ¥4.8 billion | ¥2.2 billion | ¥4.4 billion | ¥7.2 billion |
| Net income (loss) | ¥4.5 billion | ¥3.4 billion | ¥1.6 billion | ¥2.8 billion | ¥2.7 billion |
| Capital stock | ¥2.0 billion | ¥2.0 billion | ¥2.0 billion | ¥2.0 billion | ¥2.0 billion |
| Total number of issued shares (common stock) | 29,062,100 shares | 29,073,800 shares | 29,079,000 shares | 29,079,000 shares | 29,079,000 shares |
| Net assets | ¥8.9 billion | ¥11.3 billion | ¥12.4 billion | ¥13.9 billion | ¥16.2 billion |
| Total assets | ¥21.5 billion | ¥33.4 billion | ¥36.9 billion | ¥37.2 billion | ¥36.3 billion |
| Net assets per share | 307.27 yen | 390.89 yen | 430.61 yen | 495.92 yen | 562.05 yen |
| Dividend per share | 25 yen | 20 yen | 22 yen | 25 yen | 25 yen |
| Interim dividend per share | 5 yen | 10 yen | 10 yen | 10 yen | 12.5 yen |
| Basic earnings (loss) per share | 155.88 yen | 117.79 yen | 55.32 yen | 97.13 yen | 95.07 yen |
| Diluted earnings per share | 155.81 yen | 117.77 yen | Could not be retrieved | Could not be retrieved | Could not be retrieved |
| Equity-to-asset ratio | 41.6% | 33.9% | 33.7% | 37.5% | 44.7% |
| Return on equity | 66.5% | 33.7% | 13.4% | 21.0% | 18.1% |
| Payout ratio | 16.0% | 17.0% | 39.7% | 25.7% | 26.3% |
Dividend history
| Fiscal year | Annual dividend per share | Of which interim | Payout ratio (as reported, parent only) | Flag |
|---|---|---|---|---|
| FY ending 7/2025 | ¥25 | ¥12.5 | 26.3% | |
| FY ending 7/2024 | ¥25 | ¥10 | 25.7% | |
| FY ending 7/2023 | ¥22 | ¥10 | 39.7% | |
| FY ending 7/2022 | ¥20 | ¥10 | 17.0% | |
| FY ending 7/2021 | ¥25 | ¥5 | 16.0% | |
| FY ending 7/2020 | ¥8.5 | ¥3.5 | 42.6% |
Pharma Foods International
Dividends per share over time
Unit yenSource Annual securities reports
Shareholder composition
Share ownership by holder category
Pharma Foods International
Unit %Source Annual securities reports
- Financial institutions12.55%
- Securities firms2.73%
- Other corporations18.06%
- Foreign holders (institutions)6.21%
- Foreign holders (individuals)0.10%
- Individuals and others60.35%
Major shareholders
| Rank | Shareholder | Shareholding ratio | Shares held |
|---|---|---|---|
| 1 | 日本マスタートラスト信託銀行株式会社(信託口) | 10.82% | 3,122,700 |
| 2 | 金 武祚 | 7.71% | 2,227,334 |
| 3 | 株式会社PFホールディングス | 5.13% | 1,480,000 |
| 4 | 伊藤忠商事株式会社 | 5.03% | 1,452,000 |
| 5 | 益田 和二行 | 2.55% | 736,685 |
| 6 | 江崎グリコ株式会社 | 2.54% | 732,000 |
| 7 | 金 英一 | 2.33% | 672,006 |
| 8 | ロート製薬株式会社 | 2.08% | 600,000 |
| 9 | 金 千尋 | 1.76% | 509,100 |
| 10 | 益田 美玲 | 1.57% | 453,300 |
Research and development expenses and capital expenditure
| Fiscal year | Research and development | Capital expenditure |
|---|---|---|
| FY ending 7/2025 | ¥1.4 billion | ¥0.8 billion |
| FY ending 7/2020 | ¥0.4 billion | ¥0.9 billion |
Research and development expenses and capital expenditure by segment (FY ending 7/2025)
| Segment | Research and development | Capital expenditure |
|---|---|---|
| BtoC事業 | ¥13.00 million | ¥6.00 million |
| BtoB事業 | ¥0.5 billion | ¥0.4 billion |
| バイオメディカル事業 | ¥0.5 billion | ¥5.00 million |
Revenue scale in the same industry
Pharma Foods International
Source Annual securities reports of each company
Foods: 130 companies · revenue · largest first・each company’s latest fiscal year・Consolidated・Disclosed
- 1 JAPAN TOBACCOFY Dec 2025 ¥3.5T
- 2 SuntoryFY Dec 2025 ¥3.1T
- 3 ASAHI GROUPFY Dec 2025 ¥2.9T
- … 52 companies
- 56 NittenFY Mar 2026 ¥68.7B
- 57 ARIAKE JAPANFY Mar 2026 ¥67.0B
- 58 Pharma Foods InternationalThis companyFY Jul 2025 ¥65.3B
- 59 NIHON SHOKUHIN KAKOFY Mar 2026 ¥63.0B
- 60 shinobu foods productsFY Mar 2026 ¥62.0B
- … 70 companies
Workforce information
Women 102 Employees by gender
Administrative filings and published information
Workplace information filings
| Item | Value |
|---|---|
| Employees | 104 |
| Annual paid leave taken |
68.2% |
| Share of managers who are women | 33.3% |
Audit and disclosure information
| Item | Value |
|---|---|
| Audit firm | 海南監査法人 |
| Audit fees (this year, total) | ¥30.00 million |
| Non-audit fees (this year, total) | Not applicable |
| Going concern note | Cannot be determined |
| Accounting standard | Japanese GAAP |
Related books, articles and videos
Sources and methodology
Retrieved disclosed figures
Major management indicators (5 years) (28 items)
| Item | Value | Consolidated / Non-consolidated |
|---|---|---|
| Comprehensive income | ¥-3.00 million | Consolidated |
| Net cash provided by (used in) operating activities | ¥-1.1 billion | Consolidated |
| Net sales | ¥65.3 billion | Consolidated |
| Net cash provided by (used in) investing activities | ¥-0.9 billion | Consolidated |
| Cash and cash equivalents | ¥9.1 billion | Consolidated |
| Net assets | ¥11.5 billion | Consolidated |
| Ordinary income (loss) | ¥2.6 billion | Consolidated |
| Total assets | ¥32.6 billion | Consolidated |
| Return on equity | 3.2% | Consolidated |
| Equity-to-asset ratio | 35.4% | Consolidated |
| Net income (loss) attributable to owners of parent | ¥0.4 billion | Consolidated |
| Net cash provided by (used in) financing activities | ¥-4.5 billion | Consolidated |
| Basic earnings (loss) per share | 12.83 yen | Consolidated |
| Net assets per share | 399.95 yen | Consolidated |
| Dividend per share | 25 yen | Parent only |
| Net sales | ¥42.2 billion | Parent only |
| Net income (loss) | ¥2.7 billion | Parent only |
| Total number of issued shares (common stock) | 29,079,000 shares | Parent only |
| Net assets | ¥16.2 billion | Parent only |
| Ordinary income (loss) | ¥7.2 billion | Parent only |
| Total assets | ¥36.3 billion | Parent only |
| Return on equity | 18.1% | Parent only |
| Equity-to-asset ratio | 44.7% | Parent only |
| Capital stock | ¥2.0 billion | Parent only |
| Payout ratio | 26.3% | Parent only |
| Interim dividend per share | 12.5 yen | Parent only |
| Basic earnings (loss) per share | 95.07 yen | Parent only |
| Net assets per share | 562.05 yen | Parent only |
Employees (11 items)
| Item | Value | Consolidated / Non-consolidated |
|---|---|---|
| Number of employees | 613 people | Consolidated |
| Number of employees | 613 people | Consolidated |
| Wage gap between men and women (all employees) | 61.7% | Parent only |
| Average length of service (years) | 5 years | Parent only |
| Average annual salary | ¥5.50 million | Parent only |
| Average age (years) | 39.3 years old | Parent only |
| Number of employees | 136 people | Parent only |
| Number of employees | 136 people | Parent only |
| Number of employees | 136 people | Parent only |
| Wage gap between men and women (regular employees) | 68.7% | Parent only |
| Wage gap between men and women (non-regular employees) | 94.9% | Parent only |
Other disclosed items (13 items)
| Item | Value | Consolidated / Non-consolidated |
|---|---|---|
| Net sales to external customers | ¥65.3 billion | Consolidated |
| Average number of temporary employees | 155 people | Consolidated |
| Average number of temporary employees | 155 people | Consolidated |
| Number of associates accounted for using equity method | 2 companies | Consolidated |
| Write-downs of inventories | ¥-76.00 million | Consolidated |
| Depreciation | ¥0.7 billion | Consolidated |
| Number of consolidated subsidiaries | 6 companies | Consolidated |
| Rate of male employees taking childcare leave (all employees) | 50.0% | Parent only |
| Average number of temporary employees | 28 people | Parent only |
| Average number of temporary employees | 28 people | Parent only |
| Average number of temporary employees | 28 people | Parent only |
| Total return on the share price index | 221.8% | Parent only |
| Ratio of female employees in managerial positions | 33.3% | Parent only |
Shares (12 items)
| Item | Value | Consolidated / Non-consolidated |
|---|---|---|
| Number of shares held | 11,985,125 shares | Consolidated |
| Total number of shares held treasury shares etc | 206,900 shares | Consolidated |
| Number of shares | 29,079,000 shares | Consolidated |
| Shareholding ratio treasury shares etc | 0.7% | Consolidated |
| Shareholding ratio | 41.5% | Consolidated |
| Number of shares held in own name treasury shares etc | 206,900 shares | Consolidated |
| Number of voting rights | 288,581 units | Consolidated |
| Carrying amount on the balance sheet | ¥0.5 billion | Consolidated |
| Carrying amount on the balance sheet | ¥1.2 billion | Consolidated |
| Number of issues | 4 issues | Consolidated |
| Number of issues | 4 issues | Consolidated |
| Total shareholder return | 100.5% | Parent only |
Research and development (1 items)
| Item | Value | Consolidated / Non-consolidated |
|---|---|---|
| Research and development expenses | ¥1.4 billion | Consolidated |
Property and facilities (1 items)
| Item | Value | Consolidated / Non-consolidated |
|---|---|---|
| Capital expenditures | ¥0.8 billion | Consolidated |
Audit (2 items)
| Item | Value | Consolidated / Non-consolidated |
|---|---|---|
| Fees for audit and attestation services - reporting company | ¥30.00 million | Consolidated |
| Fees for audit and attestation services - total | ¥30.00 million | Consolidated |
Balance sheet (111 items)
| Item | Value | Consolidated / Non-consolidated |
|---|---|---|
| Other | ¥45.00 million | Consolidated |
| Other | ¥1.0 billion | Consolidated |
| Other | ¥1.0 billion | Consolidated |
| Other | ¥1.6 billion | Consolidated |
| Other | ¥49.00 million | Consolidated |
| Valuation difference on available-for-sale securities | ¥0.2 billion | Consolidated |
| Goodwill | ¥71.00 million | Consolidated |
| Goodwill | ¥71.00 million | Consolidated |
| Lease assets, net | ¥27.00 million | Consolidated |
| Work in process | ¥0.7 billion | Consolidated |
| Retained earnings | ¥7.7 billion | Consolidated |
| Raw materials and supplies | ¥0.9 billion | Consolidated |
| Notes receivable - trade | ¥11.00 million | Consolidated |
| Notes and accounts receivable trade | ¥5.0 billion | Consolidated |
| Merchandise and finished goods | ¥6.3 billion | Consolidated |
| Non-current liabilities | ¥1.1 billion | Consolidated |
| Non-current assets | ¥8.8 billion | Consolidated |
| Land | ¥1.2 billion | Consolidated |
| Accounts receivable - trade | ¥5.0 billion | Consolidated |
| Tools, furniture and fixtures | ¥0.5 billion | Consolidated |
| Buildings and structures, net | ¥2.1 billion | Consolidated |
| Construction in progress | ¥0.2 billion | Consolidated |
| Investments and other assets | ¥4.0 billion | Consolidated |
| Investment securities | ¥2.5 billion | Consolidated |
| Notes and accounts payable - trade | ¥1.9 billion | Consolidated |
| Property, plant and equipment | ¥4.7 billion | Consolidated |
| Income taxes payable | ¥1.5 billion | Consolidated |
| Accounts payable - other | ¥3.5 billion | Consolidated |
| Shareholders' equity | ¥11.4 billion | Consolidated |
| Machinery, equipment and vehicles, net | ¥0.7 billion | Consolidated |
| Current liabilities | ¥20.0 billion | Consolidated |
| Current assets | ¥23.9 billion | Consolidated |
| Accumulated depreciation | ¥-10.8 billion | Consolidated |
| Intangible assets | ¥0.1 billion | Consolidated |
| Cash and cash equivalents | ¥9.1 billion | Consolidated |
| Cash and deposits | ¥9.2 billion | Consolidated |
| Short-term loans payable | ¥11.4 billion | Consolidated |
| Net assets | ¥11.5 billion | Consolidated |
| Net assets | ¥11.5 billion | Consolidated |
| Total assets | ¥32.6 billion | Consolidated |
| Deferred tax assets | ¥0.5 billion | Consolidated |
| Treasury stock | ¥-0.2 billion | Consolidated |
| Valuation and translation adjustments | ¥0.2 billion | Consolidated |
| Liabilities | ¥21.1 billion | Consolidated |
| Liabilities and net assets | ¥32.6 billion | Consolidated |
| Allowance for doubtful accounts | ¥-0 | Consolidated |
| Capital surplus | ¥1.8 billion | Consolidated |
| Capital stock | ¥2.0 billion | Consolidated |
| Provision for bonuses | ¥72.00 million | Consolidated |
| Net defined benefit liability | ¥0.4 billion | Consolidated |
| Long-term loans payable | ¥0.7 billion | Consolidated |
| Electronically recorded monetary claims - operating | ¥0.2 billion | Consolidated |
| Current portion of long-term loans payable | ¥0.6 billion | Consolidated |
| Other | ¥8.00 million | Parent only |
| Other | ¥63.00 million | Parent only |
| Other | ¥0.6 billion | Parent only |
| Other | ¥0.6 billion | Parent only |
| Investments in other securities of subsidiaries and associates | ¥0.9 billion | Parent only |
| Valuation difference on available-for-sale securities | ¥0.2 billion | Parent only |
| Lease obligations | ¥19.00 million | Parent only |
| Lease assets, net | ¥22.00 million | Parent only |
| Work in process | ¥0.2 billion | Parent only |
| Life insurance funds | ¥0.4 billion | Parent only |
| General reserve | ¥30.00 million | Parent only |
| Retained earnings | ¥12.3 billion | Parent only |
| Advances received | ¥88.00 million | Parent only |
| Prepaid expenses | ¥0.4 billion | Parent only |
| Advance payments trade | ¥1.00 million | Parent only |
| Raw materials and supplies | ¥0.2 billion | Parent only |
| Notes receivable - trade | ¥28.00 million | Parent only |
| Merchandise and finished goods | ¥3.7 billion | Parent only |
| Non-current liabilities | ¥0.6 billion | Parent only |
| Non-current assets | ¥6.9 billion | Parent only |
| Land | ¥0.7 billion | Parent only |
| Accounts receivable - trade | ¥4.8 billion | Parent only |
| Tools, furniture and fixtures | ¥0.4 billion | Parent only |
| Buildings, net | ¥0.7 billion | Parent only |
| Construction in progress | ¥7.00 million | Parent only |
| Investments and other assets | ¥4.9 billion | Parent only |
| Investment securities | ¥1.6 billion | Parent only |
| Property, plant and equipment | ¥1.9 billion | Parent only |
| Income taxes payable | ¥1.4 billion | Parent only |
| Accounts payable - other | ¥4.6 billion | Parent only |
| Shareholders' equity | ¥16.1 billion | Parent only |
| Structures, net | ¥52.00 million | Parent only |
| Current liabilities | ¥19.5 billion | Parent only |
| Current assets | ¥29.4 billion | Parent only |
| Intangible assets | ¥72.00 million | Parent only |
| Cash and deposits | ¥5.3 billion | Parent only |
| Short-term loans payable | ¥10.4 billion | Parent only |
| Net assets | ¥16.2 billion | Parent only |
| Net assets | ¥16.2 billion | Parent only |
| Total assets | ¥36.3 billion | Parent only |
| Deferred tax assets | ¥30.00 million | Parent only |
| Retained earnings brought forward | ¥12.3 billion | Parent only |
| Treasury stock | ¥-0.2 billion | Parent only |
| Valuation and translation adjustments | ¥0.2 billion | Parent only |
| Liabilities | ¥20.1 billion | Parent only |
| Liabilities and net assets | ¥36.3 billion | Parent only |
| Accounts payable - trade | ¥1.9 billion | Parent only |
| Allowance for doubtful accounts | ¥-0 | Parent only |
| Capital surplus | ¥1.9 billion | Parent only |
| Legal capital surplus | ¥1.9 billion | Parent only |
| Capital stock | ¥2.0 billion | Parent only |
| Provision for bonuses | ¥7.00 million | Parent only |
| Vehicles, net | ¥5.00 million | Parent only |
| Provision for retirement benefits | ¥0 | Parent only |
| Long-term loans payable | ¥0.5 billion | Parent only |
| Shares of subsidiaries and associates | ¥2.0 billion | Parent only |
| Loans receivable to subsidiaries and affiliates | ¥14.1 billion | Parent only |
| Current portion of long-term loans payable | ¥0.5 billion | Parent only |
Statement of income (89 items)
| Item | Value | Consolidated / Non-consolidated |
|---|---|---|
| Other | ¥54.00 million | Consolidated |
| Other | ¥42.00 million | Consolidated |
| Other | ¥7.6 billion | Consolidated |
| Other comprehensive income | ¥-0.4 billion | Consolidated |
| Valuation difference on available for sale securities net of tax | ¥-0.4 billion | Consolidated |
| Amortization of goodwill | ¥53.00 million | Consolidated |
| Amortization of goodwill | ¥53.00 million | Consolidated |
| Amortization of goodwill | ¥53.00 million | Consolidated |
| Dividends from surplus | ¥-0.8 billion | Consolidated |
| Comprehensive income | ¥-3.00 million | Consolidated |
| Interest income | ¥6.00 million | Consolidated |
| Guaranty money income | ¥0.1 billion | Consolidated |
| Dividend income | ¥32.00 million | Consolidated |
| Operating income | ¥2.4 billion | Consolidated |
| Operating income | ¥2.4 billion | Consolidated |
| Non-operating income | ¥0.5 billion | Consolidated |
| Non-operating expenses | ¥0.3 billion | Consolidated |
| Net cash provided by (used in) operating activities | ¥-1.1 billion | Consolidated |
| Cost of sales | ¥12.7 billion | Consolidated |
| Gross profit (loss) | ¥52.6 billion | Consolidated |
| Net sales | ¥65.3 billion | Consolidated |
| Net sales | ¥65.3 billion | Consolidated |
| Advertising expenses | ¥36.7 billion | Consolidated |
| Net income | ¥0.4 billion | Consolidated |
| Net income | ¥0.4 billion | Consolidated |
| Net income (loss) | ¥0.4 billion | Consolidated |
| Net income (loss) | ¥0.4 billion | Consolidated |
| Gain on investments in partnership | ¥1.00 million | Consolidated |
| Loss on valuation of investment securities | ¥0.1 billion | Consolidated |
| Net cash provided by (used in) investing activities | ¥-0.9 billion | Consolidated |
| Share of loss of investments accounted for using equity method | ¥0.1 billion | Consolidated |
| Interest expenses | ¥91.00 million | Consolidated |
| Commission fees | ¥18.00 million | Consolidated |
| Commission fees | ¥4.4 billion | Consolidated |
| Fiduciary obligation fee | ¥16.00 million | Consolidated |
| Income taxes - current | ¥2.3 billion | Consolidated |
| Income taxes | ¥2.1 billion | Consolidated |
| Income taxes - deferred | ¥-0.2 billion | Consolidated |
| Foreign exchange losses | ¥1.00 million | Consolidated |
| Extraordinary loss | ¥0.1 billion | Consolidated |
| Effect of exchange rate change on cash and cash equivalents | ¥0 | Consolidated |
| Net increase (decrease) in cash and cash equivalents | ¥-6.5 billion | Consolidated |
| Research and development expenses | ¥1.4 billion | Consolidated |
| Research and development expenses | ¥1.4 billion | Consolidated |
| Income (loss) before income taxes | ¥2.4 billion | Consolidated |
| Income (loss) before income taxes | ¥2.4 billion | Consolidated |
| Ordinary income | ¥2.6 billion | Consolidated |
| Disposal of treasury stock | ¥0.9 billion | Consolidated |
| Purchase of treasury stock | ¥-0.2 billion | Consolidated |
| Subsidy income | ¥0.2 billion | Consolidated |
| Comprehensive income attributable to owners of parent | ¥-3.00 million | Consolidated |
| Net cash provided by (used in) financing activities | ¥-4.5 billion | Consolidated |
| Selling, general and administrative expenses | ¥50.2 billion | Consolidated |
| Other | ¥40.00 million | Parent only |
| Other | ¥3.00 million | Parent only |
| Dividends from surplus | ¥-0.8 billion | Parent only |
| Interest income | ¥39.00 million | Parent only |
| Dividend income | ¥26.00 million | Parent only |
| Operating income | ¥7.0 billion | Parent only |
| Non-operating income | ¥0.4 billion | Parent only |
| Non-operating expenses | ¥0.2 billion | Parent only |
| Cost of sales | ¥6.6 billion | Parent only |
| Gross profit (loss) | ¥35.6 billion | Parent only |
| Net sales | ¥42.2 billion | Parent only |
| Advertising expenses | ¥19.2 billion | Parent only |
| Net income (loss) | ¥2.7 billion | Parent only |
| Net income (loss) | ¥2.7 billion | Parent only |
| Loss on investments in partnership | ¥59.00 million | Parent only |
| Loss on valuation of investment securities | ¥86.00 million | Parent only |
| Interest expenses | ¥84.00 million | Parent only |
| Commission fees | ¥18.00 million | Parent only |
| Commission fees | ¥3.7 billion | Parent only |
| Fiduciary obligation fee | ¥21.00 million | Parent only |
| Income taxes - current | ¥2.1 billion | Parent only |
| Income taxes | ¥2.1 billion | Parent only |
| Income taxes - deferred | ¥-6.00 million | Parent only |
| Depreciation | ¥40.00 million | Parent only |
| Foreign exchange losses | ¥1.00 million | Parent only |
| Extraordinary loss | ¥2.4 billion | Parent only |
| Research and development expenses | ¥1.4 billion | Parent only |
| Income (loss) before income taxes | ¥4.8 billion | Parent only |
| Ordinary income | ¥7.2 billion | Parent only |
| Disposal of treasury stock | ¥0.9 billion | Parent only |
| Purchase of treasury stock | ¥-0.2 billion | Parent only |
| Subsidy income | ¥0.2 billion | Parent only |
| Selling, general and administrative expenses | ¥28.6 billion | Parent only |
| Provision of allowance for doubtful accounts | ¥-2.00 million | Parent only |
| Freightage expenses | ¥2.0 billion | Parent only |
| Loss on valuation of shares of subsidiaries and associates | ¥2.3 billion | Parent only |
Statement of changes in equity (4 items)
| Item | Value | Consolidated / Non-consolidated |
|---|---|---|
| Total changes during the period | ¥-38.00 million | Consolidated |
| Net changes in items other than shareholders' equity | ¥-0.4 billion | Consolidated |
| Total changes during the period | ¥2.3 billion | Parent only |
| Net changes in items other than shareholders' equity | ¥-0.4 billion | Parent only |
Statement of cash flows (37 items)
| Item | Value | Consolidated / Non-consolidated |
|---|---|---|
| Other | ¥-70.00 million | Consolidated |
| Other | ¥21.00 million | Consolidated |
| Other | ¥-8.00 million | Consolidated |
| Amortization of goodwill | ¥53.00 million | Consolidated |
| Increase decrease in notes and accounts payable trade | ¥0.7 billion | Consolidated |
| Interest expenses paid | ¥-91.00 million | Consolidated |
| Interest and dividends income received | ¥38.00 million | Consolidated |
| Interest and dividend income | ¥-38.00 million | Consolidated |
| Guaranty money income | ¥-0.1 billion | Consolidated |
| Decrease increase in notes and accounts receivable trade | ¥-1.0 billion | Consolidated |
| Subtotal | ¥0.9 billion | Consolidated |
| Loss gain on investments in partnership | ¥-1.00 million | Consolidated |
| Purchase of investment securities | ¥-64.00 million | Consolidated |
| Proceeds from sales of investment securities | ¥0 | Consolidated |
| Valuation gains (losses) on investment securities | ¥0.1 billion | Consolidated |
| Equity in earnings losses of affiliates | ¥0.1 billion | Consolidated |
| Interest expenses | ¥91.00 million | Consolidated |
| Purchase of property plant and equipment | ¥-0.9 billion | Consolidated |
| (Increase)/decrease in consumption tax/value-added tax receivables | ¥-0.6 billion | Consolidated |
| Decrease in consumption taxes payable | ¥0.2 billion | Consolidated |
| Increase (decrease) in accounts payable-other | ¥-0.4 billion | Consolidated |
| Decrease (increase) in inventories | ¥-1.1 billion | Consolidated |
| Income taxes paid | ¥-2.2 billion | Consolidated |
| Depreciation | ¥0.7 billion | Consolidated |
| Foreign exchange loss (gain) | ¥-0 | Consolidated |
| Purchase of intangible assets | ¥-15.00 million | Consolidated |
| Decrease/increase in short-term loans payable | ¥-3.5 billion | Consolidated |
| Proceeds from disposition of treasury stock | ¥0.8 billion | Consolidated |
| Regarding purchase of treasury stock | ¥-0.2 billion | Consolidated |
| Proceeds from compensation | ¥0.1 billion | Consolidated |
| Proceeds from subsidy income | ¥0.2 billion | Consolidated |
| Subsidy income | ¥-0.2 billion | Consolidated |
| Increase (decrease) in allowance for doubtful accounts | ¥-1.00 million | Consolidated |
| Increase (decrease) in provision for bonuses | ¥-0 | Consolidated |
| Increase (decrease) in net defined benefit liability | ¥-5.00 million | Consolidated |
| Dividends | ¥-0.8 billion | Consolidated |
| Repayment of long term loans payable | ¥-0.8 billion | Consolidated |
Basic indicators
| Item | Value | Consolidated / Non-consolidated | Source |
|---|---|---|---|
| Net cash provided by (used in) operating activities | ¥-1.1 billion | Consolidated | Disclosed |
| Dividend per share | 25 | Parent only | Disclosed |
| Number of employees | 613 | Consolidated | Disclosed |
| Net assets | ¥11.5 billion | Consolidated | Disclosed |
| Net sales | ¥65.3 billion | Consolidated | Disclosed |
| Operating income | ¥2.4 billion | Consolidated | Disclosed |
| Ordinary income | ¥2.6 billion | Consolidated | Disclosed |
| Net income | ¥0.4 billion | Consolidated | Disclosed |
| Total assets | ¥32.6 billion | Consolidated | Disclosed |
| Operating margin | 3.6% | Consolidated | Calculated |
| Net margin | 0.6% | Consolidated | Calculated |
| Sales per employee | 106460033 yen | Consolidated | Calculated |
| Total asset turnover | 2.0 times | Consolidated | Calculated |
| Net assets to total assets | 35.4% | Consolidated | Calculated |